CalciMedica, Inc.
CALC$0.75
$-0.25 (-24.73%)
After HoursLoading chart...
IndexN/A
Market Cap0.01B
Enterprise Value98.92B
Income$-0.01B
Sales$0.00B
EmployeesN/A
P/E-0.57
P/SN/A
P/B-14896.04
P/C-4664.93
EV/EBITDA-3521.14
EV/SalesN/A
EPS (ttm)-1.33
EarningsN/A
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Volume1.12M
Shs Outstand0.02B
Change-24.73%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
Jun 2407:01AMCalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program(prnewswire.com)07:00AMCalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data(prnewswire.com)
Mar 307:00AMCalciMedica Reports 2025 Financial Results and Provides Clinical Updates(prnewswire.com)
Jan 2811:48AMCalciMedica Pauses Kidney Study, Eyes New Trial In Pancreatitis(benzinga.com)07:00AMCalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation(prnewswire.com)
Dec 3109:30AMAirbus Clinches Contract to Supply 30 A320neo Aircraft to CALC(zacks.com)01:52AMCalciMedica (NASDAQ:CALC) Trading Down 2.1% – Time to Sell?(defenseworld.net)
Nov 1207:01AMCalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates(prnewswire.com)07:00AMCalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension(prnewswire.com)
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | $519.00K | $395.00K | $303.00K | $175.00K |
| Gross Profit | N/A | N/A | N/A | $-519.00K | $-395.00K | $-303.00K | $-175.00K |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Expenses | $24.20M | $38.08M | $14.19M | $35.43M | $29.44M | $37.20M | $28.39M |
| Operating Income | $-24.20M | $-38.08M | $-14.19M | $-35.95M | $-29.83M | $-37.50M | $-28.57M |
| Operating Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income | $-13.70M | $-34.36M | $-7.82M | $-35.82M | $-27.53M | $-37.04M | $-28.38M |
| Net Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS (Basic) | $-1.22 | $-7.65 | $-23.20 | $-23.66 | $-73.50 | $-35.85 | $-33.10 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Discover more
You may be interested in